No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LNTH240719C87500
- 1.00
- +0.65+185.71%
15min DelayClose Jul 3 12:59 ET
1.00High0.70Low
0.70Open0.35Pre Close540 Volume2.03K Open Interest87.50Strike Price53.39KTurnover47.65%IV11.24%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type0.1843Delta0.0342Gamma106.08Leverage Ratio-0.0692Theta0.0059Rho19.55Eff Leverage0.0436Vega
Intraday
- 5D
- Daily
News
Is Lantheus Holdings (NASDAQ:LNTH) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
Truist Financial analyst Richard Newitter maintains $Lantheus(LNTH.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.1% and a total average return of 15.8% over t
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $128
JonesTrading analyst Justin Walsh maintains $Lantheus(LNTH.US)$ with a buy rating, and maintains the target price at $128.According to TipRanks data, the analyst has a success rate of 32.9% and a tota
Unusual Options Activity: CVS, DKNG and Others Attract Market Bets, CVS V/OI Ratio Reaches 137.5
EST Jun 27th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Lantheus Holdings Acquires Global Rights to Life Molecular Imaging's RM2
Lantheus Holdings (LNTH) said Thursday that it is acquiring global rights of Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor for prostate and breast cancers. The company
Lantheus Expands Cancer Pipeline With $35M Acquisition of RM2 Rights
Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcome
Comments
$Cassava Sciences(SAVA.US$ : “If they can have something big, that stock triples. If they don’t, I think it drifts down. I like that risk/reward, but understand it’s speculative.”
$Lantheus(LNTH.US$ : “I think it’s great..Lantheus is terrific.”
$Lantheus(LNTH.US$ : “I think it’s great..Lantheus is terrific.”
$Lantheus(LNTH.US$ let’s go baby!
Last week’s PDUFAs:
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
20
2
Paul Blanchfield, Lantheus' President, is confident in Morgan's ability to guide the company's commercial activities and generate value. Morgan is excited about her new role and the opportunity to advance Lantheus' diverse portfolio.
1
Read more